Search results for "Inde"

showing 10 items of 7365 documents

Diabetes mellitus prevalence and control in sleep-disordered breathing: The European Sleep Apnea Cohort (ESADA) study

2014

BACKGROUND: OSA is associated with an increased risk of cardiovascular morbidity. A driver of this is metabolic dysfunction and in particular type 2 diabetes mellitus (T2DM). Prior studies identifying a link between OSA and T2DM have excluded subjects with undiagnosed T2DM, and there is a lack of population-level data on the interaction between OSA and glycemic control among patients with diabetes. We assessed the relationship between OSA severity and T2DM prevalence and control in a large multinational population.METHODS: We performed a cross-sectional analysis of 6,616 participants in the European Sleep Apnea Cohort (ESADA) study, using multivariate regression analysis to assess T2DM prev…

AdultMalePulmonary and Respiratory MedicineAdolescentPolysomnographySettore MED/10 - Malattie Dell'Apparato RespiratorioCritical Care and Intensive Care MedicineSeverity of Illness IndexRegression AnalysiCohort Studiesintermittent hypoxia insulin resistance HbA1CYoung AdultSleep Apnea SyndromesSleep Apnea SyndromeRisk FactorsPrevalenceHumansProspective StudiesIsraelAgedGlycated HemoglobinAged 80 and overCross-Sectional StudieHemoglobin A GlycosylatedRisk FactorMiddle AgedEuropeProspective StudieCross-Sectional StudiesDiabetes Mellitus Type 2Regression AnalysisFemaleCohort StudieCardiology and Cardiovascular MedicineHuman
researchProduct

Deep inspiration-induced changes in lung volume decrease with severity of asthma

2007

Summary We have previously reported that the magnitude of deep inspiration (DI)-induced bronchodilation is only slightly reduced in mild asthmatics, compared to healthy subjects. The aim of this study was to evaluate whether increased severity of asthma is associated with impairment in the ability of DI to induce changes in lung volume. Thirty-six consecutive asthmatics recruited from the Pulmonary and the Allergy Outpatient Clinics of the Institute of Respiratory Diseases of the University of Palermo were divided into 3 groups: Intermittent (I), Mild Persistent (MP) and Moderate–Severe (MS), based on GINA guidelines. Single dose methacholine (Mch) bronchoprovocations were performed in the …

AdultMalePulmonary and Respiratory MedicineAllergymedicine.medical_specialtyAdolescentVital CapacityBronchiSettore MED/10 - Malattie Dell'Apparato RespiratorioGastroenterologySeverity of Illness IndexBronchial Provocation TestsDrug Administration ScheduleLung inflationBronchoconstrictor Agents03 medical and health sciencesFEV1/FVC ratio0302 clinical medicineInternal medicineForced Expiratory VolumemedicineOutpatient clinicCorticosteroidsHumansLung volumesAlbuterol030212 general & internal medicineasthma deep inspiration lung functionMethacholine ChlorideAsthmaAgedMethacholinebusiness.industryRespiratory diseaseMiddle Agedmedicine.diseaseAsthma3. Good healthBronchodilator Agents030228 respiratory systemInhalationAnesthesiaSalbutamolMethacholineBronchodilationFemalebusinessmedicine.drugRespiratory Medicine
researchProduct

Inhaled Corticosteroids and the Beneficial Effect of Deep Inspiration in Asthma

2005

Deep inspiration-induced bronchoprotection and bronchodilation are impaired in asthma. We evaluated the effect of inhaled glucocorticosteroids on these phenomena. Two groups of subjects with asthma, 9 with moderate/severe hyperresponsiveness to methacholine, and 12 with mild/borderline hyperresponsiveness to methacholine, received inhaled fluticasone (880 microg daily) for 12 weeks. Serial bronchoprovocations were performed at Weeks 0, 6, and 12. The impact of deep inspirations on the airway response to methacholine was evaluated on the basis of inspiratory vital capacity and FEV(1). Fluticasone produced a wide spectrum of changes in the beneficial effects of deep inspiration, but the mean …

AdultMalePulmonary and Respiratory MedicineRespiratory Therapymedicine.drug_classVital CapacityRespiratory physiologySettore MED/10 - Malattie Dell'Apparato RespiratorioCritical Care and Intensive Care MedicineSeverity of Illness IndexBronchial Provocation TestsBronchoconstrictor AgentsForced Expiratory VolumeIntensive careAdministration Inhalationlung inflation asthma treatmentBronchodilationmedicineHumansMethacholine ChlorideAgedFluticasoneAsthmaInhalationbusiness.industryMiddle Agedmedicine.diseaseAsthmaBronchodilator AgentsA. Asthma and Allergyrespiratory tract diseasesAndrostadienesInhalationAnesthesiaRespiratory MechanicsFluticasoneCorticosteroidFemaleMethacholineBronchial Hyperreactivitybusinessmedicine.drugAmerican Journal of Respiratory and Critical Care Medicine
researchProduct

Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients

2008

Background Hereditary angioedema (HAE) due to C1 inhibitor deficiency is clinically characterized by relapsing skin swellings, abdominal pain attacks, and life-threatening upper airway obstruction. Treatment with androgens prevents attacks for those with this condition. Objective To examine the benefits and risks of long-term treatment with danazol. Methods Data were generated retrospectively from 118 German and Danish patients who had HAE due to C1 inhibitor deficiency and were treated with danazol from 2 months to 30 years. The frequency and severity of acute attacks were registered before and during danazol treatment, and adverse effects to the treatment were noted. Data were collected b…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAbdominal painPediatricsImmunologyDose-Response Relationship ImmunologicRisk AssessmentSeverity of Illness IndexEcallantideSeverity of illnessmedicineHumansImmunology and AllergyAdverse effectDepression (differential diagnoses)Retrospective StudiesDanazolbusiness.industryDanazolAngioedemas HereditaryEstrogen AntagonistsMiddle Agedmedicine.diseaseSurgeryDiscontinuationHereditary angioedemaFemalemedicine.symptombusinessFollow-Up Studiesmedicine.drugAnnals of Allergy, Asthma & Immunology
researchProduct

Is it possible to predict which patients with mild pneumonias will develop hypoxemia?

2009

SummaryUsually, mortality due to mild community-acquired pneumonias (CAP) (Pneumonia severity index (PSI) classes I–III) is low (<3%), but the appearance of hypoxemia significantly increases mortality. Our aim was to determine the clinical parameters associated with risk factors of developing hypoxemia in subjects with mild CAP (PSI I–III) and the clinical outcomes of the hypoxemic group.We analyzed clinical characteristics and the outcomes of patients with mild CAP and hypoxemia (PaO2/FiO2<300), in a prospective, multicenter cohort study of 1195 patients.Mild pneumonias (PSI I–III) were found in 645 cases (53.9%), of which 217 (33.6%) presented hypoxemia according to a PaO2/FiO2<300. Patie…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAdolescentCommunity-acquired pneumoniamedicine.medical_treatmentPneumonia severity indexSeverity assessmentHypoxemiaHypoxemiaPulmonary Disease Chronic ObstructiveYoung AdultCommunity-acquired pneumoniaHumansMedicineHypoalbuminemiaHypoxiaAgedMechanical ventilationCOPDbusiness.industrySeptic shockPneumoniaMiddle Agedmedicine.diseaserespiratory tract diseasesSurgeryCommunity-Acquired InfectionsRadiographyPneumoniaRisk factorsAnesthesiaFemalemedicine.symptomEpidemiologic MethodsbusinessHypoalbuminemiacirculatory and respiratory physiologyRespiratory Medicine
researchProduct

Gender Differences in Health‐Related Quality of Life Among Patients with Asthma

2004

This study has a twofold objective: 1) to explore to what extent suffering from asthma affects the HRQL of men and women differently at several stages of disease severity and 2) to analyze whether the informed poorer HRQL of asthmatic women is related to their higher scores on instruments measuring emotionally disordered symptoms. One hundred fifty-one outpatient asthmatics (84 women and 67 men) completed the Spanish versions of the Asthma Quality of Life questionnaire (AQL), as well as anxiety and depression inventories. A full history, physical examination, and pulmonary function test were performed on all subjects. Patients were classified into one of four asthma severity categories foll…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAdolescentPhysical examinationmacromolecular substancesSeverity of Illness IndexPulmonary function testingSex FactorsQuality of lifeSeverity of illnessmedicineHumansImmunology and AllergyDepression (differential diagnoses)AsthmaDepressive Disordermedicine.diagnostic_testbusiness.industryRespiratory diseaseMiddle Agedmedicine.diseaseAnxiety DisordersAsthmarespiratory tract diseasesDyspneaPediatrics Perinatology and Child HealthQuality of LifePhysical therapyAnxietyFemalemedicine.symptombusinessClinical psychologyJournal of Asthma
researchProduct

Spontaneous gastroesophageal reflux and airway patency during the night in adult asthmatics

2000

Controversies still exist on the role of nighttime gastroesophageal reflux (GER) in precipitating nocturnal asthma. We tested the relationship between GER and nocturnal bronchoconstriction by continuously and simultaneously monitoring both respiratory resistances and esophageal pH in seven asthmatics with moderate to severe GER disease. Twenty-nine GER episodes were found during the study night lasting more than 5 min (LGER) and 72 not longer than 5 min (SGER). Both long (LGER) and short (SGER) gastroesophageal refluxes were able to maintain significantly higher lower respiratory resistances (RLR) at the resolution of each GER episode (RLR(e)) with respect to baseline values. RLR, expressed…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAirway patencyPrognosiBronchoconstrictionPolysomnographySettore MED/10 - Malattie Dell'Apparato RespiratorioNocturnalEsophaguCritical Care and Intensive Care MedicineSeverity of Illness IndexGastroenterologyEsophagusInternal medicinemedicineHumansRespiratory systemAsthmaEsophageal diseasebusiness.industryAirway ResistancefungiRespiratory diseaseRefluxHydrogen-Ion ConcentrationMiddle AgedPrognosismedicine.diseaseAsthmaCircadian RhythmSurgeryGastroesophageal RefluxFemaleBronchoconstrictionmedicine.symptombusinessHuman
researchProduct

Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany

2009

Omalizumab is a humanized monoclonal anti-immunoglobulin E (IgE) antibody indicated in Europe for the treatment of uncontrolled severe persistent allergic (IgE-mediated) asthma despite optimal therapy with inhaled corticosteroids and long-acting beta(2) agonists. Between 2005 and 2007 280 patients (58% female, mean age 44+/-16 yrs., 46% on oral corticosteroids, median serum IgE level 235IU/ml) who met the EU criteria for add-on therapy with anti-IgE were treated prospectively with omalizumab by 134 physicians as part of a post-marketing surveillance trial and were followed-up for 6 months. The median follow-up time was 195 days, the patients were treated with a median dose of 450mg omalizum…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAllergyAdolescentAllergyOmalizumabOmalizumabAntibodies Monoclonal HumanizedImmunoglobulin ESeverity of Illness IndexYoung AdultQuality of lifeAdrenal Cortex HormonesForced Expiratory VolumeGermanyInternal medicineSeverity of illnessHypersensitivityHumansMedicineAnti-Asthmatic AgentsProspective StudiesChildProspective cohort studyAdverse effectAsthmaDose-Response Relationship Drugbiologybusiness.industryAntibodies MonoclonalMiddle Agedmedicine.diseaseAsthmaAntibodies Anti-IdiotypicSurgeryTreatment Outcomebiology.proteinFemaleIgETherapybusinessmedicine.drugRespiratory Medicine
researchProduct

Cigarette Smoking, But Not Sensitization toAlternaria, Is Associated with Severe Asthma in Urban Patients

2001

Hereditary susceptibility and allergen exposure have been identified as general risk factors for asthma. However, risk factors for severe asthma still remain to be identified. To further assess and quantify risk factors associated with severe asthma in adult patients apart from clinical exacerbations, 306 randomly selected subjects (mean age 40+/-17 years, 46% males) presenting to an inner city pulmonary practice between 1995 and 1996 were retrospectively investigated. Of these, 117 patients were atopic, 112 had current asthma, and 22 asthmatics had severe asthma. Risk factors associated with atopy were family history of atopy and any domestic pet ownership (OR: 3.1, 95% CI: 1.64-6.1). Asth…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAllergyUrban Populationmedicine.disease_causeSeverity of Illness IndexAtopyAllergenRisk FactorsForced Expiratory VolumeGermanyInternal medicineImmunopathologyHypersensitivitymedicineHumansImmunology and AllergyFamily historyRisk factorRetrospective StudiesAsthmabusiness.industrySmokingRespiratory diseaseUrban HealthAlternariamedicine.diseaseAsthmarespiratory tract diseasesMultivariate AnalysisPediatrics Perinatology and Child HealthImmunologyFemalebusinessJournal of Asthma
researchProduct

Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy

2015

Few data are available on the proportion of asthmatics achieving a good asthma control (according GINA guidelines) and on the level of airway inflammation during omalizumab treatment. The aim of this cross-sectional national observational study was to assess the level of control (according to GINA guidelines) achieved in a group of asthmatics on omalizumab treatment, and to characterize the factors that influence the lack of control. We studied 306 asthmatics under omalizumab treatment for a median of 32 months (range 4-120). The level of control according to GINA was good in 25.2%, partial in 47.1% and poor in 24.5% of patients (data were missing for the remaining 3.2%). Comparison between…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyExacerbationCross-sectional studyOmalizumabOmalizumabComorbiditySettore MED/10 - Malattie Dell'Apparato RespiratorioExhaled nitric oxide; Exacerbations; Comorbidities; Asthma; Omalizumab; ControlSeverity of Illness IndexComorbiditiesExacerbationsExhaled nitric oxideInternal medicineSeverity of illnessControlMedicineAnti-Asthmatic AgentHumansPharmacology (medical)Anti-Asthmatic AgentsInflammation MediatorAsthmaRespiratory Function TestAgedCross-Sectional Studiebusiness.industryBiochemistry (medical)ExacerbationMiddle Agedmedicine.diseaseComorbidityAsthmaRespiratory Function TestsCross-Sectional StudiesItalyExhaled nitric oxidePhysical therapyObservational studyAsthma; Comorbidities; Control; Exacerbations; Exhaled nitric oxide; Omalizumab; Adult; Aged; Anti-Asthmatic Agents; Asthma; Comorbidity; Cross-Sectional Studies; Female; Humans; Inflammation Mediators; Italy; Male; Middle Aged; Omalizumab; Respiratory Function Tests; Severity of Illness Index; Pulmonary and Respiratory Medicine; Biochemistry (medical); Pharmacology (medical)FemaleComorbiditieInflammation Mediatorsbusinessmedicine.drugHuman
researchProduct